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Abstract
Background: Patients with large, locally advanced cervical cancers (LACC) are challenging to treat. The purpose of
this work is to use 18F-FDG PET as planning basis for a short-course simultaneous integrated boost (SIB) in external
beam radiotherapy of LACC in order to increase tumour shrinkage and likelihood of local control.
Methods: Ten previously treated patients with LACC were included, all with pre-treatment FDG PET/CT images
available. The FDG avid tumour volume, MTV50, was dose escalated in silico by intensity modulated radiotherapy
from the standard 1.8 Gy to 2.8 Gy per fraction for the 10 first fractions; a short-course SIB. For the 18 remaining
external fractions, standard pelvic treatment followed to total PTV and MTV50 doses of 50.4 Gy and 60.4 Gy,
respectively. Photon and proton treatment were considered using volumetric modulated arc treatment (VMAT)
and intensity-modulated proton therapy (IMPT), respectively. All treatment plans were generated using the
Eclipse Treatment Planning System (TPS). The impact of tumour shrinkage on doses to organs at risk (OARs) was
simulated in the TPS for the SIB plans.
Results: Dose escalation could be implemented using both VMAT and IMPT, with a D98 ≥ 95 % for MTV50 being
achieved in all cases. The sum of the 10 fraction short-course SIB and subsequent 18 standard fractions was
compared to the standard non-SIB approach by dose volume histogram (DVH) analysis. Only marginal increase
of dose to OARs was found for both modalities and a small further increase estimated from tumour shrinkage.
Most DVH parameters showed a mean difference below 2 %. IMPT had, compared to VMAT, reduced OAR doses
in the low to intermediate dose range, but showed no additional advantage in dose escalation.
Conclusions: Planning of dose escalation based on a FDG avid boost volume was here demonstrated feasible.
The concept may allow time for enhanced tumour shrinkage before brachytherapy. Thus, this strategy may
prove clinically valuable, in particular for patients with large tumours.
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Background
Cervical cancer is one of the most common cancers
among women worldwide [1]. Standard treatment for pa-
tients with locally advanced disease is external beam radio-
therapy (EBRT) with concomitant chemotherapy followed
by brachytherapy (BT). Good clinical outcome is achieved,
but there are still about one in ten patients who suffer
from local failure and typically two out of ten experience
moderate to severe late side effects [2–4]. For BT, mag-
netic resonance (MR) based image guided adaptive brachy-
therapy (IGABT) is recommended as the best practice
[5, 6]. Patients with large tumours at time of brachytherapy
do however remain challenging to treat, particularly with-
out combining intracavitary and interstitial implants and
with limited imaging capability. The usage of interstitial im-
plants is invasive and many centres worldwide do not offer
this technique. Furthermore, there are many centres that
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still rely on 2D imaging for BT planning [7, 8]. It is there-
fore of interest to explore new EBRT strategies that may
facilitate for improved brachytherapy by reducing the com-
plexity and thus potentially improve the outcome for cer-
vical cancer patients that are challenging to treat today.
18F-fluorodeoxyglucose (FDG) is the most widely used
tracer for positron emission tomography (PET), especially in
oncological imaging. FDG PET depicts glucose metabolism,
which is increased in most malignant tumours [9]. FDG PET
has proven valuable in pre-treatment assessment of cervical
cancers, as both metabolic volume [10] and maximum stan-
dardised uptake value (SUVmax) [11] are predictive of treat-
ment response. Furthermore, in evaluating treatment
response a sustained high FDG uptake during and after
treatment may indicate continued presence of viable
tumour cells and a poor prognosis [12, 13].
Today, PET/CT images of patients with cervical cancer
are mainly utilized to detect metastatic disease [14] often
found in pelvic and para-aortic lymph nodes with potential
major impact on treatment strategies. Still, one may consider
further exploiting information from the PET images about
the primary tumour to guide radiotherapy for these patients.
In the current work we propose to escalate the dose to a
PET based metabolic target volume during the two first
weeks of external beam therapy. In this short-course ap-
proach, a simultaneous integrated boost (SIB) technique
using intensity modulation is proposed for dose escalation.
The treatment concept is investigated for patients with lo-
cally advanced cervical cancer exploring both photon and
proton intensity modulated radiotherapy. This novel concept
for external beam dose escalation early in the treatment
course may improve the subsequent brachytherapy by in-
creasing tumour shrinkage. The treatment concept may have




Ten patients with locally advanced cervical cancer were
retrospectively selected for this study, all previously
treated with curative intent according to standard clin-
ical practice at our institution. Patients with intermedi-
ate to large primary tumours were selected with PET
defined volumes ranging from 34 cm3 to 128 cm3. The
cohort had a median age of 46 years ranging from 37 to
71 years with FIGO stages ranging from 2b to 3b. This
study was approved by the regional research ethics com-
mittee (Regional Committees for Medical and Health
Research Ethics, South East Norway) and informed con-
sent was obtained from all patients.
Standard treatment and imaging
Standard treatment consists of 50.4 Gy to the planning
target volume (PTV) with 28 external beam fractions of
1.8 Gy, given 5 times a week. After around three weeks,
additional image guided high dose rate (HDR) BT to
the primary tumour is delivered in four fractions using
intracavitary implants alone, or in combination with
interstitial implants. Planning aims during brachyther-
apy, including EBRT dose, are a D90 (minimum dose to
90 % of the volume) of 85 Gy for the high risk CTV [5]
(HR-CTV) and a D98 of 95 Gy for the gross target vol-
ume (GTV), in 2 Gy equivalent doses (EQD2) assuming
α/β = 10. For organ at risks (OARs) overall D2cm
3 con-
straints (minimum dose to the 2 cm3 volume receiving
highest dose) are 70 Gy for rectum, sigmoid and small
bowel and 80 Gy for the bladder (EQD2, assuming α/β =
3). The patients also receive concomitant chemotherapy
with cisplatin (40 mg per m2) once a week to a total of
4–6 cycles depending on tolerance.
A treatment planning FDG PET/CT scan (Biograph, Sie-
mens, Erlangen, Germany) over the pelvis and abdomen had
been performed as part of clinical practice for all patients in-
cluded in this study. The FDG PET scans are acquired 60–
70 min after injection of 350 MBq (±20 %) activity. The
OSEM reconstruction algorithm (8 iterations and 4 subsets)
are used together with a 5 mm Gaussian smoothing. The
resulting PET images have slice thickness and pixel size of
2.0 mm and 2.7 mm, respectively, while the CT images have
2.0 mm and a 1.0 mm, respectively. Medical images are
imported to an Oncentra Treatment Planning System
(Version 4.3, Nucletron, an Elekta company, Veenen-
daal, The Netherlands) for treatment planning. Target
volumes and organs at risk are delineated by radiation
oncologists and the primary tumour on PET images by
nuclear medicine specialists. MR images are also rou-
tinely used in the definition of the primary tumor and
pathological lymph nodes for these patients, but were
not considered in this PET based study.
Study concept
To explore the potential of PET based EBRT dose escal-
ation, a new treatment concept is suggested. A metabolic
target volume, MTV50 within the primary tumour is
defined by auto-segmentation using 50 % of SUVmax as a
threshold. MTV50 is to be dose escalated by intensity
modulated radiotherapy from the standard mean dose of
1.8 Gy to 2.8 Gy per fraction for the 10 first fractions; a
short-course SIB. For the remaining 18 EBRT fractions,
standard treatment to the pelvic area follows (Fig. 1). By
the suggested concept, the dose to MTV50 is escalated
from an EQD2 of 49.6 Gy to 61.7 Gy during EBRT. Con-
sequently, assuming that MTV50 is fully covered by the
GTV and planning aims met during BT, a total EQD2
D98 of 107.1 Gy may be achieved for MTV50. The feasi-
bility of the short-course approach was tested in silico
using both photon and proton techniques for intensity
modulation.
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Treatment planning for both photons and protons was
performed using the Eclipse Treatment Planning System
(v.11, Varian Medical Systems, Palo Alto, CA), after import-
ing FDG PET/CT scans and RT structures. The central clin-
ical target volume (CTVcentral) included a 5 mm isotropic
expansion of the primary tumour (GTVtumour, defined from
PET images), the uterus, both parametria and proximally
3 cm of the vagina. The central planning target volume
(PTVcentral) was created from CTVcentral with margins of 7,
10 and 10 mm in the left/right, anterior/posterior and super-
ior/inferior direction, respectively. In this study, only pelvic
treatment was investigated including elective (CTVE) and
malignant (CTVN) pelvic lymph nodes. The lymph node
planning target volume (PTVE-N) was created by a 5 mm
isotropic expansion of the lymph node CTVs. No additional
margin was created for MTV50. The bladder, rectum, sig-
moid, cauda equina and small bowel (including the entire
potential space up to the upper level of the L4 vertebrae)
were defined as OARs.
The standard non-SIB plans were normalised to a
1.8 Gy mean dose for the PTVunion (union of PTVcentral
and PTVE-N) per fraction. For local dose escalation,
MTV50 was simultaneously boosted to 2.8 Gy per fraction.
To avoid de-escalation of the surrounding target volume,
PTVunion subtracted with a 10 mm isotropic expansion of
GTVtumour was used for normalization in the SIB plans.
All plans had to fulfil the criteria of PTVunion having a
D98 ≥ 95 % of the prescribed dose. The MTV50 D98 was
also evaluated in the SIB plans. In the optimization, to re-
duce OAR doses, one dose volume histogram (DVH) con-
straint was applied to limit maximum dose and additional
individually adjusted constraints used to reduce inter-
mediate doses. For each patient, the standard homo-
geneous plan was created prior to the dose escalated
SIB-plan, where the latter was optimized with stand-
ard DVH constraints scaled according to 10 fractions.
For the relevant OARs, DVH parameters V30Gy, V45Gy
and D2cm
3 were calculated for all 28 fractions and
used together with the D98 criteria for PTVunion in
plan evaluation. Population based DVHs (including
standard deviations) were created for comparing the
total dose from the short-course SIB to the standard
approach for both VMAT and IMPT.
All photon plans were created with the volumetric in-
tensity modulated arc therapy (VMAT) technique Rapid-
Arc (Varian Medical Systems, Palo Alto, CA). Each plan
consisted of two full arcs with collimator angles of 30° and
330° and one isocenter. A 6 MV photon beam from a Var-
ian Clinac iX with a 120 leaf Millenium MLC (5 mm and
10 mm central and outer resolution, respectively) was
used with a 2.5 mm dose calculation grid.
For proton therapy, intensity modulated proton ther-
apy (IMPT) was considered using two opposing lateral
fields and one posterior field. In this study, multifield
optimization (MFO) was applied, optimizing spots from
all three fields simultaneously. Beam line data with a
nominal energy range of 70 to 250 MeV were available
for treatment planning. The dose distribution was cal-
culated using a 2.5 mm dose grid and assuming a gen-
eric relative biological effectiveness (RBE) of 1.1 [15].
Furthermore, a spot spacing of 5 mm was used together
with 5 mm circular lateral margins and proximal and dis-
tal margins of 5 mm to account for range uncertainties.
The current study is based on pre-treatment PET/CT
images and changes in patient anatomy may impact the
doses received by the target volumes and OARs. To
study the dosimetric impact of tumour shrinkage, OARs
(bladder, rectum and sigmoid) were shifted systematic-
ally towards the tumour as a single direction expansion
of the respective organ volumes in the dose planning
system. It was assumed that the tumor is spherical and
isotropically shrinking, with a one-to-one association be-
tween tumour radius reduction and OAR shift. Based on
the mean tumour volume found for patients included in
this study and potential tumour regressions of 30 and
50 % [16, 17] OAR shifts of 3 mm and 5 mm, respect-
ively were simulated.
Statistical analysis
Student’s paired t-tests were used for statistical evalu-
ation of DVH parameters in comparing the short-course
SIB approach to standard therapy and VMAT to IMPT.
In all statistical evaluation, p-values below 0.05 were
considered statistically significant and p-values below
0.001 truncated and displayed as p < 0.001.
Fig. 1 Timeline illustrating doses to MTV50 and PTVunion during fractionated treatment following the proposed treatment concept. In this example
with a schedule of 5 fractions per week, the short course SIB is completed after 11 days, 12 days before onset of brachyterapy
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Results
For the patients included, MTV50 had a mean volume of
35 ± 6 cm3 as compared to average volumes for the
GTVtumour and PTVunion of 69 ± 9 cm
3 and 1474 ± 42 cm3,
respectively. SUVmax ranged from 12 to 31 with a median
value of 23. Figure 2 shows axial and sagittal images and
dose distributions for one case, comparing 10 SIB fractions
to 10 standard non-SIB fractions for both VMAT and
IMPT. For this case the dose escalation only had a minor
effect on the surrounding volumes for both modalities,
also for OARs situated close to the boost volume. In gen-
eral, the dose escalation was straightforward to implement
for both VMAT and IMPT, with a D98 ≥ 95 % for MTV50
being achieved in all SIB plans. This means that the
MTV50 was successfully dose escalated from 18 Gy to
28 Gy during the first 10 fractions regardless of modality.
Pair wise statistics showed the MTV50 D98 to be higher in
IMPT plans than VMAT plans (p < 0.05), but the popula-
tion based mean values were very similar; 27.3 Gy and
26.9 Gy, respectively.
Figure 3 shows population based DVHs for target vol-
umes and OARs for both photon and proton therapy.
The sum of the short-course SIB (10 fractions) and the
subsequent 18 standard fractions is compared to a
standard, 28 fraction non-SIB approach. For GTVtumour
and PTVunion, the inter-patient variation is small in the
standard approach with adequate coverage for both
VMAT and IMPT. In the novel approach inter-patient
variation is greater particularly for GTVtumour, as the
relative size of the boost volume varies between pa-
tients. Target volume coverage, however, remains good
when dose escalating. Looking at the OARs, all the dose
distributions are almost identical when comparing the
SIB approach to the standard approach. For bladder
however, a slight difference is visible in the low to inter-
mediate dose-range with about 1 Gy increase for the
SIB as compared to standard fractionation for VMAT.
In general however, patient to patient variations in
OAR doses due to anatomical differences were up to
about 10 Gy (Fig. 3), which are far greater than the in-
crease from dose escalation. A summary of OAR DVH
parameters V30Gy, V45Gy and D2cm
3 is presented in
Table 1, where the total treatment following the short-
course approach is compared to standard fractionation
for both modalities. Pair wise statistics showed signifi-
cantly higher values for many parameters, but with a
mean difference less than 2 % in all cases except for
V30Gy in bladder using VMAT (3 % increase).
Fig. 2 a Axial and sagittal views of the FDG PET/CT scan for one patient (GTVtumour volume 66 cm
3, MTV50 volume 31 cm
3 and SUVmax 31). Target
volumes PTVunion (blue), GTVtumour (pink) and MTV50 (green) and OARs bladder (yellow), rectum (light blue) and bowel (brown) outlined. b Axial and
sagittal views of the obtianed dose distributions. Fractions 1–10 are shown for both VMAT and IMPT plans, comparing a standard homogenious
plan (top) to the corresponding short-course SIB with additional 1.0 Gy per fraction to MTV50 (bottom)
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Fig. 3 Population based DVHs for all 10 patients for target volumes and OARs (mean in solid lines and mean +/− 1 SD in dotted lines). Standard
external beam therapy with 28 fractions of 1.8 Gy to PTVunion is compared to the total dose using the short-course approach (SIB) with 10 fractions with
2.8 Gy to MTV50 followed by 18 standard fractions for both VMAT and IMPT
Table 1 Overall dose volume histogram parameters for OARs
Bladder Rectum Sigmoid Bowel*





VMAT Stand. 81.3 ± 2.2 48.0 ± 2.2 51.2 ± 0.1 90.8 ± 1.5 72.1 ± 1.9 50.9 ± 0.1 96.0 ± 1.3 75.0 ± 4.4 51.0 ± 0.1 448 ± 56 218 ± 31 51.7 ± 0.1
SIB 83.5 ± 2.3† 48.7 ± 2.3 51.9 ± 0.3† 91.1 ± 1.5 73.1 ± 2.0† 51.4 ± 0.2† 96.6 ± 1.4 75.3 ± 4.4 51.1 ± 0.1 452 ± 59 220 ± 31 51.8 ± 0.2
IMPT Stand. 60.1 ± 2.4 44.3 ± 2.3 51.0 ± 0.1 84.7 ± 1.7 70.3 ± 1.7 50.9 ± 0.1 87.7 ± 3.6 74.1 ± 4.0 50.8 ± 0.1 313 ± 44 206 ± 30 51.3 ± 0.1
SIB 60.8 ± 2.4† 45.1 ± 2.3† 51.2 ± 0.2† 85.2 ± 1.7† 71.0 ± 1.8† 51.2 ± 0.2† 88.2 ± 3.5 74.4 ± 4.0 50.9 ± 0.1 316 ± 45† 208 ± 31† 51.6 ± 0.3
Dose volume histogram parameters comparing the overall treatment following the short-course concept to a standard fractionated schedule
Values are mean ± standard deviation of the mean
Abbreviations: Stand standard plan of 1.8Gy X 28, SIB sum of 10 fraction SIB and 18 fraction standard plan
*Entire potential space within irradiated area,
†Significant pair wise difference between Stand and SIB parameter
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In the dosimetric sensitivity analysis, OAR shifts of
3 mm and 5 mm towards the primary tumour were sim-
ulated. The resulting D2cm
3 per fraction (EQD2) in the
SIB plans for the shifted OARS were compared to corre-
sponding values for the planned static situation (Table 2).
For bladder and rectum, such shifts gave a D2cm
3 in-
crease per fraction from around 0.2 Gy to 0.4 Gy com-
pared to the planned, original SIB.
Discussion
In this study a PET-based short-course approach for
dose escalation in treatment of locally advanced cervical
cancer has been presented. The results show that both
photon and proton therapy allows for a 10 Gy dose es-
calation of the boost-volume during the 10 first fractions
with only a minor increase of OAR doses. Comparing
VMAT to IMPT for standard homogeneous plans, our
results were in line with previous planning studies for
cervical cancer with reduced low to intermediate OAR
doses using protons [18–20]. In dose escalation however,
IMPT did not show an additional advantage over
VMAT. This follows as both modalities succeeded in in-
creasing the dose to the FDG avid tumour sub-volume
without noteworthy increasing OAR doses compared to
a standard homogeneous plan.
Although cervix tumours shrink during treatment
[16, 17], a significant number of patients still present
with large or asymmetric tumours at time of brachy-
therapy. This remains a challenge as these patients are
expected to benefit from higher target doses [21]. At
the same time, it is more difficult to achieve full target
coverage for large tumours. Increased tumour remis-
sion before brachytherapy is therefore desired, particu-
larly as many centers worldwide do not offer the
possibility of interstitial implants. Dose escalation deliv-
ered 2–3 weeks prior to brachytherapy may provide
such additional tumour shrinkage, being an important
incentive for the short-course approach. Dose escal-
ation of an FDG avid sub-volume was investigated in
this study, but other boost volume definitions may also
be considered. With a marginal increase in OAR D2cm
3
from the EBRT dose escalation, only small changes to
standard dose constraints are expected for brachytherapy.
The suggested concept for external beam dose escalation
may therefore be feasible, potentially facilitating for im-
proved brachytherapy.
Anatomical changes occur during treatment of cervical
cancer and are of particular concern when applying a
SIB with high fraction doses and steep dose gradients.
Even though the cervix shows less motion than the
uterus [22], daily image guidance with soft tissue con-
trast will be vital for clinical implementation of any dose
escalation. Cone beam CT imaging (CBCT) with subse-
quent couch correction may be used to avoid overlap be-
tween the high dose area and OARs. It can nevertheless
be treatment sessions where adequate couch corrections
are not possible and in these cases the standard plan can
serve as a robust backup plan similar to the plan of the
day concept [23]. A drinking protocol and markers for
targeting of the boost volume [23] may also be necessary
to reduce geometric uncertainties. Intra fraction motion
is generally found to be smaller than inter fraction mo-
tion [22] with cervical displacement found to be less
than 5 mm in most cases [24]. This motion can however
currently not be corrected for and may also increase
slightly with treatment time [22], thus potentially being
larger during IMPT than VMAT.
The dosimetric effects of anatomical changes will be
greater for IMPT than VMAT as proton stopping power
is more sensitive to tissue changes than the correspond-
ing photon interaction coefficients. These effects have
previously been investigated for standard and dose esca-
lated intensity modulated radiotherapy (IMRT) of cervix
cancer [25, 26] and for IMPT with a SIB for prostate
cancer [27]. Herrera et al. [26] analyzed dose escalation
of a central target volume including the uterus over 28
fractions using deformable registration of weekly CBCT
images. They found, compared to planned values, over-
dosage of adjacent OARs correlating with tumour
shrinkage and recommended frequent plan adaptation.
In our approach however, a smaller PET based volume
confined well within the GTV is to be dose escalated. A
greater distance between the high dose area and OARs
gives lower OAR doses, and our strategy is thus ex-
pected to be less sensitive to random organ motion.
Also, dose escalation is limited to the 10 first fractions,
Table 2 Dosimetric sensitivity of OAR clinical maximum dose, D2cm
3
Bladder [Gy] Rectum [Gy] Sigmoid [Gy]
Param/Plan VMAT IMPT VMAT IMPT VMAT IMPT
Standard 1.77 ± 0.00 1.75 ± 0.00 1.75 ± 0.00 1.75 ± 0.01 1.75 ± 0.01 1.74 ± 0.00
SIB 1.92 ± 0.04 1.80 ± 0.01 1.85 ± 0.02 1.82 ± 0.02 1.81 ± 0.02 1.78 ± 0.01
SIB 3 mm shift 2.11 ± 0.08 2.02 ± 0.06 2.04 ± 0.04 2.00 ± 0.05 1.93 ± 0.05 1.88 ± 0.05
SIB 5 mm shift 2.23 ± 0.10 2.20 ± 0.09 2.16 ± 0.06 2.15 ± 0.06 2.02 ± 0.08 1.97 ± 0.08
Dosimetric sensitivity analysis estimating increase of D2cm
3 to OARs from shifts towards the high dose area potentially caused by tumour shrinkage
Values are EQD2 per fraction (α/β = 3) and in mean ± standard deviation of the mean
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leaving less time for systematical anatomical changes. As
the tumour may regress during the course of the treat-
ment, adjacent OARs may experience a systematic shift
towards the high dose area in addition to random day to
day variations. However, as tumour shrinkage is ex-
pected to be limited in the two first weeks of treatment
[16, 17, 26], the extra OAR dose estimated from this
effect (Table 2) may only potentially be achieved for a
few fractions towards the end of dose escalation. After
completion of dose escalation however, repeated imaging
should be considered for possible adaptation of the fol-
lowing standard non-SIB plan. Such timing would also
be consistent with previous clinical trials in adaptive
PET based dose painting of head and neck cancer where
plan adaptation were implemented after 10 treatment
fractions [28, 29].
In dose painting, biological imaging reflecting the
spatial distribution of radiobiological properties is used
to prescribe an inhomogeneous dose distribution to the
tumour [30]. It may be carried out as dose painting by
numbers (DPBN) [31], where the voxel dose is deter-
mined by the corresponding biologic voxel value, or as
dose painting by contours (DPBC), where an image
based biologic target volume is dose escalated. The tech-
nique has proven feasible and there are several ongoing
and completed phase 1 and 2 studies applying FDG PET
based dose-painting for head and neck and non-small-
cell lung cancer (NSCLC) [32]. The two-level DPBC
approach presented here is to our knowledge the first
investigation of PET-based dose painting for cervical
cancer. The choice of 50 % of SUVmax as a threshold in
boost volume segmentation is consistent with previous
clinical implementation of DPBC for NSCLC and head
and neck cancer [29, 33]. Further investigations of the
short-course concept for PET based dose escalation may
also include DPBN as it, compared to DPBC, is sug-
gested to be less sensitive to PET reconstruction param-
eters [34].
The usage of a SIB during EBRT of locally advanced
cervical cancer is not uncommon, but the aim has typic-
ally been to treat gross disease in the parametria or
metastatic lymph nodes [35, 36]. The motivation is to
reduce total treatment time [37] compared to the con-
ventional approach with sequential boosting of lymph
nodes. Acceptable acute toxicity and promising tumour
control is reported [35, 36], demonstrating that SIB is a
feasible approach in treatment of cervical cancer. There
are other studies investigating high external fraction
doses to the primary tumour using photons and protons,
but then instead of and not in addition to brachytherapy
[38, 39]. A recent analysis reviewing treatment outcome
for different boost modalities, did however find a signifi-
cantly increased mortality risk in patients receiving
external boost only [40]. The dose escalation concept
suggested here is therefore not meant to replace brachy-
therapy. It is rather meant to facilitate for improved
brachytherapy by possibly increasing tumour shrinkage.
Conclusions
A short-course approach to PET based dose escalation
has been presented and found feasible. Clinical imple-
mentation of this concept will require the use of cur-
rently available image guidance techniques. In addition
to expected increase of tumour control, this approach
may enhance tumour shrinkage before brachytherapy.
Thus, this novel treatment concept may prove clinically
valuable, in particular for patients with large or asym-
metric tumours.
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